Edition:
United States

Audentes Therapeutics Inc (BOLD.OQ)

BOLD.OQ on NASDAQ Stock Exchange Global Market

41.12USD
4:00pm EDT
Change (% chg)

$-1.69 (-3.95%)
Prev Close
$42.81
Open
$43.02
Day's High
$43.66
Day's Low
$40.96
Volume
141,670
Avg. Vol
125,193
52-wk High
$46.12
52-wk Low
$15.74

Chart for

About

Audentes Therapeutics, Inc. is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the... (more)

Overall

Beta: --
Market Cap(Mil.): $1,500.98
Shares Outstanding(Mil.): 36.74
Dividend: --
Yield (%): --

Financials

  BOLD.OQ Industry Sector
P/E (TTM): -- 244.89 34.04
EPS (TTM): -2.65 -- --
ROI: -33.25 -5.30 13.11
ROE: -34.35 -6.83 15.11

BRIEF-Audentes Announces Data From First Dose Cohort Of ASPIRO

* AUDENTES ANNOUNCES CONTINUING POSITIVE DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

May 16 2018

BRIEF-Audentes Therapeutics Reports Qtrly Loss Per Share $0.74

* AUDENTES THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

May 09 2018

BRIEF-Audentes Therapeutics CEO Matthew Patterson's 2017 Total Compensation Was $6.9 Million

* AUDENTES THERAPEUTICS INC SAYS CEO MATTHEW PATTERSON'S 2017 TOTAL COMPENSATION WAS $6.9 MILLION – SEC FILING Source text for Eikon: (http://bit.ly/2KknZ9F) Further company coverage:

Apr 27 2018

BRIEF-Audentes Therapeutics Q4 Loss Per Share ‍$0.82

* AUDENTES THERAPEUTICS REPORTS FOURTH QUARTER 2017 AND FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

Mar 08 2018

BRIEF-Wellington Management Group Llp Reports 10.85 pct Passive Stake In Audentes Therapeutics As Of Jan 31, 2018

* WELLINGTON MANAGEMENT GROUP LLP REPORTS 10.85 PERCENT PASSIVE STAKE IN AUDENTES THERAPEUTICS INC AS OF JANUARY 31, 2018 - SEC FILING‍​ Source text - (http://bit.ly/2nZykxi) Further company coverage:

Feb 12 2018

BRIEF-Audentes Therapeutics Says Public Offering Of 5.75 Mln Shares Priced At $35/Share

* AUDENTES THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

Jan 24 2018

BRIEF-Audentes Therapeutics To Offer $150 Million Of Common Stock In Public Offering​

* AUDENTES THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Jan 23 2018

BRIEF-Audentes Announces Positive Interim Data From First Dose Cohort Of Aspiro

* AUDENTES ANNOUNCES POSITIVE INTERIM DATA FROM FIRST DOSE COHORT OF ASPIRO, A PHASE 1/2 CLINICAL TRIAL OF AT132 IN PATIENTS WITH X-LINKED MYOTUBULAR MYOPATHY

Jan 04 2018

Competitors

  Price Chg
Amicus Therapeutics, Inc. (FOLD.OQ) $16.51 -0.58
Sanofi SA (SASY.PA) €67.71 -0.60

Earnings vs. Estimates